A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Tom Nolan reviews this week’s research Microplastics and nanoplastics (MNPs) are being found just about everywhere we look, and they have now been found in our brains. A report in Nature Medicine ...

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual ...

Menopause significantly increases the risk of cardiovascular diseases in women due to a drop in estrogen levels.

GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...